UMCG account plan
academic hospital, all transplants
At a glance
UMCG is the academic hospital of the Northern Netherlands, with FY2025 operating revenue of EUR 2,056.6m and 13,670 staff.
UMCG (University Medical Center Groningen) is the academic hospital of the Northern Netherlands, delivering highly complex patient care, education and training, and research. It is a partnership between the public-law Academisch Ziekenhuis Groningen and the University of Groningen's Faculty of Medical Sciences, with group companies including Ommelander Ziekenhuis Groningen and UMCG Ambulancezorg. In FY2025 consolidated operating revenue was EUR 2,056.6m, mostly from health insurers under the Health Insurance Act (EUR 1,352.5m), and the result for the year was EUR 27.0m. It had 13,670 staff at 31 December 2025 and handled 491,156 outpatient visits and 27,363 admissions.
Business units
UMCG Zorg (patient care)
EUR 1,760.3m FY2025 operating revenue (about 85% of combined segment revenue)Academic and top-referral care, including comprehensive centres for oncology, transplantation and acute care; the Transplant Centre is the largest in the Netherlands. Operating-room treatments rose to 45,011 in 2025 from 40,051. The segment result was EUR 27.0m, as insurer contract indexation was offset by collective labour agreement raises and inflation.
UMCG O&O (education and research)
EUR 304.0m FY2025 operating revenue (about 15% of combined segment revenue)Research in three institutes (MoHAD, PRECISION and Health in Context) and education including medicine, dentistry and 39 medical specialist training programmes. In 2025 it produced 4,238 publications and a record 307 PhDs and won EUR 117.8m in grants; the segment result of EUR 7.6m is passed to the University of Groningen.
Ommelander Ziekenhuis Groningen
A regional hospital in Scheemda with EUR 187.5m of Zvw revenue, back to a EUR 4.6m result in 2025 under a recovery plan. A framework agreement gives one-off insurer supplements of EUR 13m over 2025-2027, and UMCG converts its EUR 10.1m subordinated loan into capital in 2026.
Strategic priorities
- Koers30 strategy
- The five-year strategy adopted at the end of 2025 adds impact as a fourth core task and rests on four gamechangers: room for self-direction, appropriate care and prevention, data/technology/AI, and sustainability. Implementation starts in 2026.
- AI to save professional time
- UMCG's AI strategy targets saving professional time and increasing patient self-service: language models draft answers to about 8,000 patient messages a month with Epic, and ChatUMCG is available to all staff.
- Regional care networks and concentration
- Works with Martini Ziekenhuis, Isala and Frisius MC, leads regional plans such as the Zorgviewer, and prepares for government-driven concentration of complex care.
- Margin rebuilding
- The EBITDA norm rises from 4.5% to 5.0% in 2028 and 5.5% from 2030 to carry rising capital charges; a working capital reduction target of about EUR 150m is set.
- Climate-neutral hospital
- Target to be circular and climate neutral by 2035; the 2025 CO2 footprint was 56,237 tonnes (-3%).
- Valorisation and innovation ecosystem
- The dean wants Groningen to be Europe's number one valorisation hotspot in health, with shared facilities on the Healthy Ageing Campus and AI on Lifelines and clinical cohort data.
Investments and deals
- Building programme to 2035
- Masterplan Bouw on the Healthy Ageing Campus includes a new laboratory building of more than 30,000 m2 and twelve new operating rooms opening in 2026; EUR 98.2m was invested in tangible fixed assets in 2025.
- Shared Care Noord
- A shared electronic patient record with three regional hospitals, going live in 2027; EPD investment to date is EUR 36.2m.
- ERP replacement
- The Werklicht programme replaces the ERP system through a tender, with EUR 6.2m invested to date.
- AI Factory and AI lab
- UMCG supports the AI Factory coming to Groningen (construction expected 2026, opening 2027) and created an AI Acceleration Lab and an AI Compliance Agency.
Challenges and risks
- Staff shortages
- Retention and capacity are top risks; the Netherlands must find 100,000 new healthcare workers in the next three years.
- Cost inflation and thin margins
- Single-entity EBITDA margin was 4.3% in 2025 against a 4.5% norm, with rising expensive drugs, energy costs and capital charges.
- Building programme risk
- Cost prices, capital charges and construction labour shortage are named risks of the programme to 2035.
- Integration and certification of AI
- Professionals' distrust, the Medical Device Regulation certification wall and an integration maze of legacy IT slow AI adoption.
- Cybersecurity
- Cybersecurity and digital resilience are a top risk, with preparation for the NIS2-based Cyber Security Act under way.
What leadership says
“We need you to help us solve the boring problems”
“We absolutely need to create autonomous systems to be able to replace the doctors and nurses we don't have in the next 20 years”
“Data-driven healthcare is everything.”
Where a supplier can help
- Administrative relief with AI
- The AI strategy to save professional time, and the explicit ask to help solve the boring problems, favour suppliers of documentation, ambient notes and workflow automation that integrate with Epic.
- Integration and compliance support
- The legacy integration maze and the Medical Device Regulation certification wall create demand for integration platforms and regulatory support, screened through the AI Compliance Agency.
- Construction and fit-out of new facilities
- The building programme to 2035, including a laboratory building and new operating rooms, opens doors for medical equipment, construction and facility suppliers.
- ERP and shared patient record projects
- The ERP replacement and Shared Care Noord going live in 2027 need implementation, data migration and change management partners.
- Cost and sustainability savings
- Margin norms rising to 5.5% and the 2035 climate-neutral target favour offers that cut energy, waste and working capital.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like UMCG?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- Jaardocument UMCG 2025 (annual report and financial statements)
- UMCG (University Medical Center Groningen) is the academic hospital of the Northern Netherlands: a partnership between the public-law Academisch Ziekenhuis Groningen and the University of Groningen's Faculty of Medical Sciences, with group companies including Ommelander Ziekenhuis Groningen (OZG) and UMCG Ambulancezorg.
- FY2025 consolidated operating revenue was EUR 2,056.6m (2024: EUR 1,989.6m), of which EUR 1,352.5m came under the Health Insurance Act (Zvw); the result for the year was EUR 27.0m (2024: EUR 29.0m), and EUR 34.6m including the education and research (O&O) result passed to the university.
- Scale: 13,670 staff at 31 December 2025 (12,335.2 average FTE), 491,156 outpatient visits, 27,363 admissions, 45,011 operating-room treatments; 4,238 publications, a record 307 PhDs and EUR 117.8m in research grants won.
- New five-year strategy Koers30 (adopted end 2025) adds "impact" as a fourth core task and is built on four gamechangers: room for self-direction, appropriate care and prevention, data/technology/AI, and sustainability.
- Heavy investment cycle: EUR 98.2m spent on tangible fixed assets in 2025; a building programme to 2035 on the Healthy Ageing Campus (a 30,000+ m2 laboratory building, twelve new operating rooms in 2026), an ERP replacement (programme Werklicht) and Shared Care Noord, a shared electronic patient record with three regional hospitals going live in 2027.
- Margin pressure: single-entity EBITDA margin 4.3% against an internal norm of 4.5%, raised to 5.0% (2028) and 5.5% (from 2030) to carry rising capital charges; consolidated EBITDA EUR 104.6m, solvency 38.0%, liquidity EUR 292m.
- AI is a strategic lever: an in-house AI assistant (ChatUMCG) for all staff since 27 November, a Programma Toegepaste AI, and support for the AI Factory coming to Groningen (construction expected 2026, opening 2027).
- Main risks named: staff retention and capacity, concentration of specialist care, cost inflation (expensive drugs, energy), the building programme and cybersecurity; the paediatric heart surgery centre (CCH) paused planned operations from 15 September 2025 to early January 2026.
- Board: Ate van der Zee (chair), Stephanie Klein Nagelvoort-Schuit (vice-chair), Wiro Niessen (dean), Paulina Snijders (CFO); supervisory board chaired by Geert ten Dam; auditor PwC.
- The Titanic of healthcare: UMCG is betting on autonomous systems (Stephanie Klein Nagelvoort at NCAS'26)
- Vice-chair Stephanie Klein Nagelvoort used her NCAS'26 keynote (Drachten) to describe Dutch healthcare as being on the Titanic, with executives listening to the music while the ship goes down.
- Three figures frame the crisis: healthcare heading for 20% of GNP, 1 in 4 workers needed in care (100,000 new workers needed in three years), and a 15-year gap in healthy life expectancy between socioeconomic groups.
- UMCG's AI strategy rests on two goals: saving professional time and increasing patient self-service.
- With Epic, UMCG uses large language models to draft answers to about 8,000 patient messages a month and to summarise records in 16 seconds instead of seven minutes; ambient notes are being explored.
- Obstacles named: professionals' distrust, the Medical Device Regulation "certification wall" and an "integration maze" of legacy IT; UMCG created an AI Acceleration Lab and an AI Compliance Agency.
- She pitched the North (Lifelines cohort of 167,000 participants, the national AI Factory) and asked tech companies to "help us solve the boring problems".
- Interview with Dean Wiro Niessen: valorization as an opportunity to benefit society and patients
- Wiro Niessen, UMCG board member and Dean of the Faculty of Medical Sciences, wants UMCG to "do much more in the field of valorization" to increase impact on health and healthcare.
- He draws on founding Quantib (2012) with Erasmus MC: GE Healthcare was the launching customer, the company grew to about 45 people, developed eight FDA-approved products and was taken over by Radnet in 2022.
- His recipe for Groningen: think big because "Not everything will be a success", build an innovation ecosystem around health with shared physical and digital facilities, the Healthy Ageing Campus among them, on the Boston model.
- He calls data-driven health central and hoped the AI factory would come to Groningen, citing LifeLines and UMCG clinical cohorts as a strong base for AI innovation.
- He points researchers to Business Generator Groningen and the UMCG Innovation Center and says UMCG values researchers who innovate as well as teach and research.
Questions about UMCG
What is UMCG?
UMCG (University Medical Center Groningen) is the academic hospital of the Northern Netherlands, delivering complex patient care, education and research in partnership with the University of Groningen.
What was UMCG's revenue in 2025?
Consolidated operating revenue was EUR 2,056.6m in FY2025, with a result for the year of EUR 27.0m.
How many people work at UMCG?
UMCG had 13,670 staff at 31 December 2025, with an average of 12,335.2 FTE.
Who leads UMCG?
The executive board is chaired by Ate van der Zee, with Stephanie Klein Nagelvoort-Schuit as vice-chair, Wiro Niessen as dean and Paulina Snijders as CFO.
What is UMCG's strategy?
Koers30, adopted at the end of 2025, adds impact as a fourth core task and focuses on self-direction, appropriate care and prevention, data/technology/AI, and sustainability.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)